Abstracts tagged "Mortality"

Abstract Number: 0667 • ACR Convergence 2021
Active Screening for Gout Permits Identifying a Larger Cardiovascular Population at High Mortality Risk
Silvia Ruiz-Simón¹, Irene Calabuig², Miguel Gómez-Garberí³ and MARIANO ANDRES⁴, ¹Universidad Miguel Hernández, Alicante, Spain, ²Hospital General Universitario de Alicante, Alicante, Spain, ³Hospital Universitario San Juan de Alicante, San Juan de Alicante, Spain, ⁴Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: We have recently noted by active screening that about a third of gout cases in the cardiovascular population is not registered in records (Calabuig,…
Abstract Number: 1302 • ACR Convergence 2021
Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study
Saira Sheikh¹, Cheng-Chung Wei², Dana Tegzova³, William Stohl⁴, Ricardo Acayaba de Toledo⁵, Tamara Mucenic⁶, Mauricio Abello Banfi⁷, Kathleen Maksimowicz-McKinnon⁸, Carlos Abud-Mendoza⁹, Sandra Navarra¹⁰, Mercedes Garcia¹¹, Ignacio Garcia-De La Torre¹², Regina Kurrasch¹³, Sofia Fernandes¹⁴, Julia Harris¹⁵, Saima Muzaffar¹⁴, Norma Lynn Fox¹³, Andrew Liu¹⁶, Holly Quasny¹⁷ and David Roth¹³, ¹University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ²Institute of Medicine, Chung Shan Medical University; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan (Republic of China), ³Institute of Rheumatology, Prague, Czech Republic, ⁴University of Southern California Keck School of Medicine, Los Angeles, CA, ⁵Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil, ⁶Hospital Moinhos de Vento, Porto Alegre, Brazil, ⁷Centro Integral de Reumatología del Caribe, Barranquilla, Colombia, ⁸Henry Ford Hospital, Wayne State University, Detroit, MI, ⁹Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatología y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ¹⁰University of Santo Tomas Hospital, Manila, Philippines, ¹¹Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ¹²Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, ¹³GlaxoSmithKline, Collegeville, PA, ¹⁴GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ¹⁵GlaxoSmithKline, Uxbridge, United Kingdom, ¹⁶GlaxoSmithKline, Brentford, United Kingdom, ¹⁷GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Belimumab (BEL) is a recombinant IgG1λ monoclonal antibody that is approved for treatment of systemic lupus erythematosus (SLE). Although clinical studies of BEL have…
Abstract Number: 0083 • ACR Convergence 2021
Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome
Tali Eviatar¹, Stanley Niznik², Nancy Agmon-Levin² and Daphna Paran³, ¹Tel Aviv Sourasky Medical Center, Givataim, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel
Background/Purpose: Cardiac valve involvement in the APS is prevalent, necessitating valve surgery in about 5% of the patients. Data regarding valve surgery outcomes in APS…
Abstract Number: 0684 • ACR Convergence 2021
Extended Report: Successful Treatment anti-MDA5 Antibody-positive Interstitial Lung Disease with Plasma Exchange Therapy
Yoshiyuki Abe¹, Masahiro Kogami², Makio Kusaoi², Kurisu Tada³, Ken yamaji⁴ and Naoto Tamura³, ¹Juntendo University School of Medicine, Tokyo, Japan, ²Juntendo University, Tokyo, Japan, ³Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, ⁴Juntendo University School of Medicine Internal Medicine and Rheumatology, Tokyo, Japan
Background/Purpose: This study was extended report from our previous study that “Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy” (Rheumatology…
Abstract Number: 1372 • ACR Convergence 2021
Outcomes and Risk Factors for Respiratory Failure in Patients with Scleroderma Associated with ILD
Soumyasri Kambhatla¹, Augustine Manadan² and Amy Trang², ¹Rush University, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Scleroderma is associated with underlying ILD. About 48% those with diffuse cutaneous SSc and 26% of those with limited cutaneous SSc were found to…
Abstract Number: 0090 • ACR Convergence 2021
Subcutaneous Sarilumab in Hospitalized Patients with Moderate-severe COVID-19 Infection Compared to the Standard Care: An Open-label Randomized Clinical Trial
Sebastián C Rodriguez-García¹, Isidoro Gonzalez-Alvaro¹, Francisco Abad-Santos², Azucena Bautista-Hernández³, Lucio García-Fraile³, Juan Pablo Baldivieso-Achá⁴, Jesús Sanz-Sanz³ and Rosario Garcia de Vicuña¹, ¹Rheumatology Service. La Princesa University Hospital, Madrid, Spain, ²Clinical Pharmacology Service. Clinical Research and Clinical Trials Unit. La Princesa University Hospital, Madrid, Spain, ³Division of Infectious Diseases, Internal Medicine Service. La Princesa University Hospital, Madrid, Spain, ⁴Rheumatology Department. La Princesa University Hospital, Madrid, Spain
Background/Purpose: Many uncertainties remain for IL-6 blockers on the management of COVID-19 such as the optimal time of intervention, the schedule of administration and predictors…
Abstract Number: 0689 • ACR Convergence 2021
Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-based Cohort
Vanessa Kronzer¹, Bradly Kimbrough², Cynthia Crowson³, John Davis¹, Marie Holmqvist⁴ and Floranne Ernste¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Previous epidemiologic studies defined dermatomyositis (DM) using international codes of diseases (ICD) codes or Bohan & Peter 1975 criteria, and most were not population-based.…
Abstract Number: 1379 • ACR Convergence 2021
Serum Levels of the Soluble Receptor for Advanced Glycation Endproducts Are Prospectively Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Isabella Atzeni¹, Yehya Al-Adwi², Berber Doornbos-van der Meer², Anniek Van Roon², Caroline Roozendaal¹, Andries Smit², Alja J. Stel², Harry Van Goor², Tji-Joong Gan¹, Johanna Westra² and Douwe J Mulder², ¹University of Groningen, University Medical Centre Groningen, Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading causes of death in Systemic Sclerosis (SSc). Markers for early detection of…
Abstract Number: 0106 • ACR Convergence 2021
COVID-19 Mortality and Hospitalization Risk in Patients with Rheumatic Diseases: A Single Center Retrospective Cohort Study
Mousa Albalwi, Ben Brintz, Srinivasan Beddhu, Guo Wei and Julie Thomas, University of Utah, Salt Lake City, UT
Background/Purpose: Following SARS-CoV-2 infection, patients with rheumatic diseases seem to have similar or slightly poorer outcomes compared with those without rheumatic disease. However, robust data…
Abstract Number: 0779 • ACR Convergence 2021
Predictors of Mortality in a Series of 1528 Brazilian Childhood-onset Systemic Lupus Erythematosus Patients
Ana Paula Sakamoto¹, Clovis Artur Silva², Aline Islabão³, Glaucia Novak⁴, Beatriz Molinari⁴, Rosa Pereira², Claudia Saad-Magalhães⁵, Gleice Clemente⁶, Melissa Fraga⁶, Daniela Petry Pioto⁷, Claudio Len⁸, Rogerio do Prado⁷ and Maria Terreri⁸, ¹Federal University of So Paulo (UNIFESP), São Paulo, Brazil, ²Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit, Hospital da Criança de Brasília Jose Alencar, Brasilia, DF, Brazil, ⁴Pediatric Rheumatology Unit, Children’s Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Division, São Paulo State University (UNESP) – Faculdade de Medicina de Botucatu, Botucatu, Botucatu, Brazil, ⁶Universidade Federal de São Paulo, São Paulo, Brazil, ⁷Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, SP, Brazil, ⁸Unifesp, São Paulo, Brazil
Background/Purpose: Childhood-onset Systemic lupus erythematosus (cSLE) is an inflammatory autoimmune disease known for its complex and variable clinical presentation and disease course. Its severity may…
Abstract Number: 1393 • ACR Convergence 2021
All-cause Mortality in a Hospital Ascertained Cohort with Giant Cell Arteritis: A Longitudinal Population-level Data Linkage Cohort Study
Helen Keen¹, Warren Raymond², Susan Lester³, David Preen², Charles Inderjeeth⁴, Catherine Hill⁵ and Johannes Nossent², ¹University of Western Australia, Daglish, Australia, ²University of Western Australia, Perth, Australia, ³Rheumatology Department, The Basil Hetzel Institute, The Queen Elizabeth Hospital, Adelaide, Australia, ⁴University of Western Australia, Nedlands, Perth, Australia, ⁵Queen Elizabeth Hospital, Woodville, Australia
Background/Purpose: Giant Cell Arteritis (GCA) is the most common primary vasculitis in high income countries and ischemic complications of GCA include blindness and stroke. The…
Abstract Number: 0110 • ACR Convergence 2021
Mortality in 2020 Due to COVID-19 in U.S. Adults with Rheumatic Diseases: Data from a Large, National, Multi-Rheumatic Disease Registry
Kaleb Michaud¹, Sofia Pedro², Rebecca Schumacher³, Mukund Kumar¹, Bryant England¹ and Alison Freifeld¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Forward Databank, Wichita
Background/Purpose: Recent studies have detailed the excess death due to COVID-19 during the pandemic, yet few have examined these rates within a rheumatic disease population…
Abstract Number: 0851 • ACR Convergence 2021
Application of a Modified Recursive Feature Elimination Machine Learning Algorithm to Select Predictors of Mortality in Those with and Without Osteoarthritis
Siyeon Kim¹, Siqi Xiang¹, Liubov Arbeeva¹, Carolina Alvarez¹, Amanda Nelson¹, Yvonne Golightly¹, Leigh Callahan², Michael Kosorok¹ and Becki Cleveland³, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, ³Thurston Arthritis Research Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC
Background/Purpose: Radiographic osteoarthritis (rOA) and joint symptoms at the knee and hip are predictors of mortality. However, questions remain about the nature of the relationship…
Abstract Number: 1427 • ACR Convergence 2021
Reduction of Cardiovascular Disease and Mortality versus Risk of New Onset Diabetes with Statin Use in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sophie Dell’Aniello², Sofia Pedro³, Kaleb Michaud⁴ and Samy Suissa⁵, ¹University of Nebraska Medical Center, Bellevue, NE, ²Center for Clinical Epidemiology, Lady Davis Research Institute - Jewish General Hospital, Montréal, QC, Canada, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Center for Clinical Epidemiology, Lady Davis Research Institute - Jewish General Hospital;Depts of Epidemiology and Biostatistics and of Medicine, McGill University, Montréal, QC, Canada
Background/Purpose: The risks of death and of type 2 diabetes mellitus (T2DM) are increased in RA mainly due to inflammation mediated accelerated cardiovascular disease (CVD)…
Abstract Number: 0246 • ACR Convergence 2021
Macrophage Activating Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Biological Drugs
Betul Sozeri¹, Kenan Barut², Erdal Atalay³, Aysenur Pac Kisaarslan⁴, Semanur Ozdel⁵, Ozge Altug⁶, Ferhat Demir¹, Balahan Makay⁷, Nuray Aktay Ayaz⁸, Ersen Acar⁹, Fatih Haslak², Erdal Sag¹⁰, Mehmet YILDIZ², Ummusen Kaya Akca¹⁰, Amra Adrovic², Yelda Bilginer¹⁰, Hakan Poyrazoglu¹¹, Erbil Unsal⁷, Ozgur Kasapcopur¹² and Seza Ozen³, ¹University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Faculty of Medicine, Pediatric Rheumatology, İstanbul, Turkey, ³Hacettepe University Faculty of Medicine, Pediatric Romatology, Ankara, Turkey, ⁴Erciyes University Medical Faculty, Pediatric Rheumatology, Kayeri, Turkey, ⁵Ankara Dr.Sami Ulus Gynecology and Pediatrics Research and Training Hospital, Pediatric Rheumatology, Ankara, Turkey, ⁶Dr Behcet Uz Children's Hospital, Pediatric Rheumatology, Izmir, Turkey, ⁷Dokuz Eylul University Faculty of Medicine, Pediatric Rheumatology, Izmir, Turkey, ⁸Istanbul University, Faculty of Medicine, Pediatric Rheumatology, İstanbul, Turkey, ⁹Novartis, Istanbul, Turkey, ¹⁰Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ¹¹Erciyes University Faculty of Medicine, Pediatric Rheumatology, Kayseri, Turkey, ¹²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) is the most acute and severe form of JIA. Despite the substantial evidence supporting the effectiveness of biologic drugs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].